R9Z Stock Overview
A biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.57 |
| 52 Week High | HK$1.20 |
| 52 Week Low | HK$0.53 |
| Beta | 0 |
| 1 Month Change | -20.28% |
| 3 Month Change | -5.79% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| R9Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.0% | 0.7% | -0.7% |
| 1Y | n/a | -2.1% | 10.1% |
Return vs Industry: Insufficient data to determine how R9Z performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how R9Z performed against the German Market.
Price Volatility
| R9Z volatility | |
|---|---|
| R9Z Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R9Z's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine R9Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 150 | Tian Wenzhi | www.immuneonco.com |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamentals Summary
| R9Z fundamental statistics | |
|---|---|
| Market cap | €243.64m |
| Earnings (TTM) | -€49.56m |
| Revenue (TTM) | €965.03k |
252.5x
P/S Ratio-4.9x
P/E RatioIs R9Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R9Z income statement (TTM) | |
|---|---|
| Revenue | CN¥7.29m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥7.29m |
| Other Expenses | CN¥381.68m |
| Earnings | -CN¥374.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,135.65% |
| Debt/Equity Ratio | 14.3% |
How did R9Z perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/15 07:44 |
| End of Day Share Price | 2025/01/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Wu | Morgan Stanley |